The solute carrier SLC15A4 is required for optimal trafficking of nucleic acid-sensing TLRs and ligands to endolysosomes.
The solute carrier SLC15A4 is required for optimal trafficking of nucleic acid-sensing TLRs and ligands to endolysosomes.
复制标题
DOI:
10.1073/pnas.2200544119
复制
发表时间:
2022-04-05
影响因子:
11.1
通讯作者:
中科院分区:
文献类型:
--
作者:
A large body of evidence has indicated that recognition of self-nucleic acids by endosomal toll-like receptors (TLRs) is central to the pathogenesis of lupus-like systemic autoimmunity in spontaneous mouse models, and the solute carrier SLC15A4 is required for this recognition. Here we describe a mechanism in which SLC15A4 is a major contributor to the proper trafficking of TLRs and their ligands to endolysosomes, wherein recognition and signaling is initiated. This finding supports ongoing efforts to identify pharmacologic inhibitors for this carrier as a means to treat lupus and other inflammatory disorders. A function-impairing mutation (feeble) or genomic deletion of SLC15A4 abolishes responses of nucleic acid–sensing endosomal toll-like receptors (TLRs) and significantly reduces disease in mouse models of lupus. Here, we demonstrate disease reduction in homozygous and even heterozygous Slc15a4 feeble mutant BXSB male mice with a Tlr7 gene duplication. In contrast to SLC15A4, a function-impairing mutation of SLC15A3 did not diminish type I interferon (IFN-I) production by TLR-activated plasmacytoid dendritic cells (pDCs), indicating divergence of function between these homologous SLC15 family members. Trafficking to endolysosomes and function of SLC15A4 were dependent on the Adaptor protein 3 (AP-3) complex. Importantly, SLC15A4 was required for trafficking and colocalization of nucleic acid–sensing TLRs and their ligands to endolysosomes and the formation of the LAMP2+VAMP3+ hybrid compartment in which IFN-I production is initiated. Collectively, these findings define mechanistic processes by which SLC15A4 controls endosomal TLR function and suggest that pharmacologic intervention to curtail the function of this transporter may be a means to treat lupus and other endosomal TLR-dependent diseases.
登录
查看更多内容
影响因子:
4.4
作者:
Lewis, Colleen J.;Cobb, Brian A.
通讯作者:
Cobb, Brian A.
影响因子:
30.8
作者:
Han, Jian-Wen;Zheng, Hou-Feng;Zhang, Xue-Jun
通讯作者:
Zhang, Xue-Jun
影响因子:
64.8
作者:
Honda, K;Ohba, Y;Taniguchi, T
通讯作者:
Taniguchi, T
DOI:
10.4049/jimmunol.1201477
发表时间:
2012-12-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
Baccala R;Gonzalez-Quintial R;Schreiber RD;Lawson BR;Kono DH;Theofilopoulos AN
通讯作者:
Theofilopoulos AN
DOI:
10.1038/nrd4626
发表时间:
2015-08
期刊:
Nature reviews. Drug discovery
影响因子:
--
作者:
Lin L;Yee SW;Kim RB;Giacomini KM
通讯作者:
Giacomini KM